[Recalled] BD BBL Sensi Disc Piperacillin/Tazobactam- 100/10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231691 and 231692¿ — There is a possibility of reproducibility, accuracy, and/or QC failures in ant
Regulators flagged this product in an official safety action. Here is what the notice says and what it means for owners.
Recall details
| Product | BD BBL Sensi Disc Piperacillin/Tazobactam- 100/10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231691 and 231692¿ |
|---|---|
| Brand / manufacturer | Becton Dickinson & Co. |
| Category | device |
| Issuing authority | FDA_DEVICE |
| Reference | Z-1037-2024 |
| Country of notice | United States |
| Risk level | Class II |
| Hazard type | recall |
| Notice date | 08 January 2024 |
| EAN / barcode | 00382902316916 |
Why it was recalled
According to the FDA_DEVICE notice, the identified hazard is: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
This Class II recall concerns device products distributed in United States and was recorded by FDA_DEVICE. Recalls in this category are published so that owners, retailers, and importers can identify affected units and act quickly.
What to do if you own this product
Check whether your unit is affected and follow the authority's guidance before further use.
Read the full official notice →
Related recalls from Becton Dickinson & Co.
This page indexes a public government recall notice for reference. We do not sell or verify this product; always confirm the current status on the authority's official site.